Skip to main content
Top
Published in: BioDrugs 1/2010

01-12-2010 | Case Report

Crohn’s Disease in a Child

Unusual Presentation with Severe Osteoporosis

Authors: Ricardo Ferreira, Dr Susana Almeida

Published in: BioDrugs | Special Issue 1/2010

Login to get access

Abstract

Crohn’s disease is a chronic inflammatory bowel disease characterized by transmural, granulomatous inflammation. In paediatric-onset Crohn’s disease, the most frequent clinical features are abdominal pain, diarrhoea, fatigue and weight loss. Delayed puberty, growth retardation and osteoporosis might, however, be the predominant signs of the disease. This paper reports the case of a 13-year-old girl with Crohn’s disease diagnosed at the age of 11 years, with classic gastrointestinal symptoms in the previous few months, but with severe osteoporosis at onset. The child has been on infliximab therapy for 1 year, with complete control of the disease. Therapy with infliximab appears to influence bone metabolism, bone formation and resorption, and that improvement seems to be independent of the clinical response to the drug. Infliximab has recently been approved for paediatric use, which has been a great improvement for a group of patients lacking therapeutic options.
Literature
1.
go back to reference Reinshagen M. Osteoporosis in inflammatory bowel disease. J Crohn’s Colitis 2008; 2(3): 202–7CrossRef Reinshagen M. Osteoporosis in inflammatory bowel disease. J Crohn’s Colitis 2008; 2(3): 202–7CrossRef
2.
go back to reference Ali T, Lam D, Bronze MS, et al. Osteoporosis in inflammatory bowel disease. Am J Med 2009; 122: 599–604PubMedCrossRef Ali T, Lam D, Bronze MS, et al. Osteoporosis in inflammatory bowel disease. Am J Med 2009; 122: 599–604PubMedCrossRef
3.
go back to reference Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn’s disease. Aliment Pharmacol Ther 2004; 20: 607–14PubMedCrossRef Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn’s disease. Aliment Pharmacol Ther 2004; 20: 607–14PubMedCrossRef
4.
go back to reference Hommes D, Baert F, van Assche G, et al. Management of recent onset Crohn’s disease: a controlled, randomized trial comparing step-up and top-down therapy [abstract]. Gastroenterology 2005; 129(1): 371CrossRef Hommes D, Baert F, van Assche G, et al. Management of recent onset Crohn’s disease: a controlled, randomized trial comparing step-up and top-down therapy [abstract]. Gastroenterology 2005; 129(1): 371CrossRef
5.
go back to reference Baldassano R, Braegger CM, Escher J, et al. Infliximab (Remicade) therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol 2003; 98(4): 833–8PubMedCrossRef Baldassano R, Braegger CM, Escher J, et al. Infliximab (Remicade) therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol 2003; 98(4): 833–8PubMedCrossRef
6.
go back to reference Bascietto C, De Angelis L, Bizzarri B. Infliximab as a first-line therapy in newly diagnosed Crohn’s Disease (CD) promotes long-term sustained remission and alters the course of the disease. J Pediatr Gastroenterol Nutr 2005; 40: 2–16CrossRef Bascietto C, De Angelis L, Bizzarri B. Infliximab as a first-line therapy in newly diagnosed Crohn’s Disease (CD) promotes long-term sustained remission and alters the course of the disease. J Pediatr Gastroenterol Nutr 2005; 40: 2–16CrossRef
7.
go back to reference Wynands J, Belbouab R, Candon S, et al. Twelve month follow-up after successful infliximab therapy in pediatric Crohn disease. Pediatr Gastroenterol Nutr 2008; 46(3): 293–8CrossRef Wynands J, Belbouab R, Candon S, et al. Twelve month follow-up after successful infliximab therapy in pediatric Crohn disease. Pediatr Gastroenterol Nutr 2008; 46(3): 293–8CrossRef
8.
go back to reference Stephens MC, Shepansky MA, Mamula P, et al. Safety and steroid-sparing experience using IFX for Crohn’s disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 104–11PubMedCrossRef Stephens MC, Shepansky MA, Mamula P, et al. Safety and steroid-sparing experience using IFX for Crohn’s disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 104–11PubMedCrossRef
Metadata
Title
Crohn’s Disease in a Child
Unusual Presentation with Severe Osteoporosis
Authors
Ricardo Ferreira
Dr Susana Almeida
Publication date
01-12-2010
Publisher
Springer International Publishing
Published in
BioDrugs / Issue Special Issue 1/2010
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.2165/11586240-000000000-00000

Other articles of this Special Issue 1/2010

BioDrugs 1/2010 Go to the issue

EditorialNotes

Foreword